Skip to content
Monday 17 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,750.11
-0.21%
DAX
26,440.31
0.00%
CAC 40
8,636.80
0.00%
STOXX 50
6,539.59
0.00%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Sunday 01 September 2024 5:57 am  |  Updated:  Thursday 29 August 2024 5:53 pm

Curing cancer and cleaning our oceans? Here’s why I’m betting on biotech

By: Andrew Craig

Add as a preferred source on Google
Richard Branson-backed testing site lays off 40 per cent of its workers
Richard Branson-backed testing site lays off 40 per cent of its workers

Something that can cure cancer and clean our oceans? Biotech sounds too good to be true, but some things really are just like magic, writes Andrew Craig

In the last century, technology has transformed the human experience across the world and lifted several billion people out of poverty. This has been super-charged in recent decades by the arrival of the internet, smart phones, AI and machine learning, and created trillion-plus dollar companies and household names like Apple, Amazon, Google and Microsoft. Tech has also been the underlying driver of US shares, having delivered an average annual return of more than 10 per cent a year for more than a century.

Biotech is next. Why? Because our biggest remaining challenges as a species concern biological systems.

We create real wealth by solving human problems – and most of our remaining problems are all about biology – whether that is curing cancer, rolling back environmental degradation or generating clean power. Biology has a huge role to play. Few people realise just how much the industry is about to give all of us. Sir Arthur C. Clarke, the British author who gave us 2001: A Space Odyssey, famously stated as one of his three laws that “any sufficiently advanced technology is indistinguishable from magic”.

In ‘Our Future is Biotech’ I highlight a great deal of the ‘magic’ going on out there already today.

I think it is fair to say that when most people hear the word “biotech” they assume it refers to healthcare and to the development of drug therapies in the main. That is certainly a huge focus for the industry but a key point I make in the book is that this is about a great deal more than just healthcare. In healthcare the industry has already delivered “miracle cures” for several diseases, and there is a great deal more to come, and soon.

Biotech companies will solve our most intractable problems; from cancer to dementia and elderly care, as well as numerous mental health conditions including, for example, depression. All of this, and the emerging field of longevity, bring the possibility of us being able to live much longer and healthier lives. Many serious scientists believe that 70 or even 80 or 90 could soon be “the new 40” for many of us alive today.

Read more

Patent cliff fuels Novartis’ $1.5bn swoop for London biotech

Hikma produces generic drugs

Perhaps more important still, biotech can and will be able to roll back environmental degradation and help clean our rivers and oceans, revolutionise agriculture and clean power generation, and even super-charge the processing power of our computers with new “biological” computing. For example, we may not be too many years away from being able to store vast amounts of data without using any electricity.

When extolling the virtues of the biotechnology industry I always have three main “tangible” goals.

First, to highlight what could likely be the biggest investment of the next few decades.

Secondly, to raise awareness of the number of opportunities that should be life changing for your health, and mental health. The industry is delivering so much now to help us understand complicated areas such as the right nutrition for you personally, and the importance of things like cold exposure, breathing, sleep, movement and diet for our health, happiness and longevity. The middle third of the book is all about “biotech and you” and covers these topics in more detail.

And the third thing I really want to pass on is a sunnier disposition and a material improvement in peoples’ outlook, mood and conception of the world we live in – given just how revolutionary this stuff is going to be for our species. I’d like to think that many of the ideas laid out in the book could just, well, put a spring in your step.

Biotech means that we can all live better, safer, healthier, wealthier, happier and longer lives. 

Andrew Craig is author of ‘How to Own the World’ and new book ‘Our Future Is Biotech’, available to order now

Read more

ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • Opinion

Categories

  • Opinion

People & Organisations

  • Biotech
  • health
  • pharmaceuticals
  • technology

Trending Articles

  • Is the Zeekr 9X Super Hybrid the new luxury SUV to beat?

  • Grandparents fund university degrees to avoid inheritance tax net

  • Aldi boss wades into supermarket ‘price-gouging’ row

  • Brompton Bicycle sues former adviser for ‘professional negligence’

  • Revolut chatbot goes rogue by charging users to cancel subscription

More from Morning Wire

  • Patent cliff fuels Novartis’ $1.5bn swoop for London biotech

    Healthcare
    Hikma produces generic drugs
  • ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

    Business Wire
  • The former African gold miner taking on the billionaire Issa brothers

    Markets
    Screenshot showing July 2026 news article layout with no specific categories or tags on a general news/business website
  • Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform

    Business Wire
  • Verdiva Bio Initiates Phase 1 Study of VRB-103, a Selective Oral Amylin Peptide Analog With Weekly Dosing Potential

    Business Wire
  • Clinigen Appoints Greg Skalicky as Chief Executive Officer

    Business Wire
  • Verdiva Bio Appoints Cardiometabolic Leader Steve Marso as Chief Medical Officer

    Business Wire
  • GXP-Storage Expands UK Capacity with Third Restricted-Access Facility at Raunds, Northamptonshire

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook